skip to main content

Rituximab hepatitis B reactivation risk — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRheumatological PharmacologyRituximab hepatitis B reactivation riskSCE Rheumatology

A 48-year-old man is due rituximab and screening shows hepatitis B core antibody positive, surface antigen negative and HBV DNA pending. What is the most appropriate management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: AAntiviral prophylaxis before rituximab

Discuss antiviral prophylaxis and hepatology input before rituximab is the single best answer because rituximab can reactivate hepatitis B even after previous exposure. The stem is testing management choice, not isolated recall, so the relevant clinical pattern and risk context determine the answer. Start methotrexate with folic acid and monitoring is less suitable because it fits a different clinical pattern or a different treatment threshold; Begin high-dose glucocorticoids immediately, Urgent joint aspiration and culture and Use NSAID therapy and physiotherapy do not address the key discriminator in this vignette. Clinical pearl: in SCE-style rheumatology questions, autoantibodies, imaging and synovial fluid findings should be interpreted with the whole phenotype.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/musculoskeletal-conditions